Taiwan’s biomedical industry is growing rapidly, with biotech and healthcare companies exceeding $55 billion in market value. The 2024 Taiwan Healthcare+ Expo spotlights five industries: smart healthcare, regenerative medicine, precision diagnostics, biotech pharmaceuticals, and advanced medical devices. This event showcases Taiwan’s role as a healthcare innovation hub in Asia-Pacific. Moreover, it explores emerging trends shaping the biotech and medical sectors. The 2024 Healthcare+ Expo highlights these dynamic industries, showcasing how advancements in technology are paving the way for future medical developments across the region.
Smart Healthcare: AI and Big Data Are the Future Powers Behind Medical Innovation
Advancements in artificial intelligence (AI) are rapidly transforming healthcare services worldwide. AI technologies are driving innovation in diagnostics, treatment, and wellness, reshaping the industry at an unprecedented pace. Taiwan is emerging as a leader in smart healthcare, showcasing groundbreaking solutions at the forefront of this transformation.
Compal’s subsidiary, HippoScreen Neurotech Corp, developed the Stress EEG Assessment system, or SEA for short. The system records 90 seconds of brainwave signals (EEG) and uses AI to deliver quantifiable stress evaluation data. Physicians use this tool to enhance the accuracy of mental health diagnoses, streamlining clinical decision-making.
Acer Medical introduced innovative AI tools for medical diagnostics. Its “AI Diabetic Retinopathy Diagnosis” technology interprets fundus images with 93% accuracy, aiding early detection of eye diseases. Meanwhile, Acer’s “AI Bone Density Screening” system analyzes chest X-rays to estimate bone density, providing a quick and efficient method for assessing bone health.
Regenerative Medicine: Harnessing Stem Cells, AI, miRNA, and Advanced Technologies for Next-Generation Therapies
Regenerative medicine is regarded as one of the most disruptive biomedical technologies today. By repairing or replacing damaged tissues and organs, it is redefining traditional approaches to treating degenerative diseases and cancer.
BIONET Corp. has developed a “Next-Generation Exosome Technology” that integrates AI to precisely analyze miRNA expression levels, enabling accurate prediction of disease indications.
In stem cell therapy, DuoGenic StemCells’ “PCP Blood Cell Purification Technology” can convert stem cells into M2 macrophages, which are used to alleviate pain associated with degenerative arthritis. Meanwhile, Taiwan Advance Bio-Pharmaceutical Inc.” Mesenchymal Stem Cell Therapy” is being developed in collaboration with several medical institutions to improve the quality of life for patients with spinal cord injuries.
Precision Diagnostics: Genomic Technology Powers Personalized Medicine Advances
Precision diagnostics is revolutionizing healthcare by leveraging genomic data to support clinical decision-making and enable personalized medicine. This approach tailors treatments to individual patients, improving outcomes and reducing risks. Innovators worldwide are driving these advancements, introducing cutting-edge genomic tools that are transforming the healthcare landscape. Current global technologies in precision diagnostics include CRISPR-based gene editing tools, liquid biopsy for cancer detection, and next-generation sequencing (NGS) for genomic profiling. Among the top companies in this field, Abbott focuses on diagnostic and medical devices, GE Healthcare specializes in MedTech solutions, and Roche leads in in vitro diagnostics and therapeutic products. Furthermore, Taiwan is emerging as a key player in smart healthcare, showcasing groundbreaking solutions that are shaping the future of this transformation.
At the Expo, Pharmigene’s “PGx Pharmacogenomics Testing” showcased a delivery of 99% accuracy in medication dosage recommendations and adverse reaction assessments. This tool offers healthcare providers precise guidance for drug administration, minimizing errors and enhancing patient safety. With its reliability, it marks a major step forward in personalized prescribing practices.
Welgene Biotech developed the “Comprehensive Chromosomal Gene Array (array CGH)” for detecting minute chromosomal abnormalities with high precision. This technology plays a vital role in rare disease research, advancing Taiwan’s contributions to global genetic studies. Meanwhile, cancer gene testing has seen significant progress. New technologies analyze over 300 cancer-related genes in one test, providing patients with accurate diagnoses and tailored treatment plans.
Biotech Pharmaceuticals: Advancements in Drug Development and CDMO Services
As the biotech pharmaceutical sector experiences rapid growth, innovations in new drug development and Contract Development and Manufacturing Organization (CDMO) services are driving its progress. These advancements are enabling the industry to meet increasing global healthcare demands.
Meribank Biotech focuses on stem cell-based drug development, conducting in-depth research on treatments for brain and lung diseases. Meanwhile, Ever Supreme Bio Technology Co., Ltd. specializes in immune cell drug development, aiming to advance therapies for solid tumors. These efforts are making significant strides in combating complex diseases.
Advanced Medical Devices: Smart Technologies Enhancing Healthcare Accessibility
Recently, the rapid advancement of medical devices has significantly upgraded healthcare technology. These innovations are making healthcare more accessible and effective. Looking at the local electronics giant, ASUS, innovations in the field are apparent. Here, ASUS has introduced the LU800 Wireless Handheld Ultrasound, a software-based ultrasound system with multiple imaging modes. This device helps healthcare professionals make accurate diagnoses with ease.
Moreover, AUO Corporation’s subsidiary, AUO Health, has developed a Pulse Detection System and Tongue Image Capture System. These devices digitize and visualize traditional Chinese medicine diagnostics, enabling more precise evaluations based on pulse and tongue analysis.
Additionally, LEADTEK Research Inc. has launched a Wearable Blood Oxygen Monitor, integrating blood oxygen levels, heart rate variability, and autonomic nervous system monitoring. This device provides comprehensive sleep quality analysis, offering valuable insights for personal health management.
The Future of Healthcare Technology in the Asia-Pacific Region
As healthcare technology continues to evolve, five key sectors are driving innovation across the Asia-Pacific region. These include smart healthcare, regenerative medicine, precision diagnostics, biotech pharmaceuticals, and advanced medical devices.
These advancements are reshaping healthcare services and creating a more competitive and collaborative landscape within the supply chain. Consequently, the region is positioning itself as a global hub for medical innovation and health management.
https://www.geneonline.com/2024-taiwan-healthcare-expo-innovations-in-five-key-industries/

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE